Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

s13046-022-02264-x.pdf (2.51 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2022-02-14

Llicència de publicació

cc by (c) Archilla Ortega, Adrià et al, 2022
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/183764

Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1186/s13046-022-02264-x

Resum

Immunotherapy has emerged as a promising strategy for boosting antitumoral immunity. Blockade of immune checkpoints (ICs), which regulate the activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells has proven clinical benefits. Antibodies targeting CTLA-4, PD-1, and PD-L1 are IC-blockade drugs approved for the treatment of various solid and hematological malignancies. However, a large subset of patients does not respond to current anti-IC immunotherapy. An integrative understanding of tumor-immune infiltrate, and IC expression and function in immune cell populations is fundamental to the design of effective therapies. The simultaneous blockade of newly identified ICs, as well as of previously described ICs, could improve antitumor response. We review the potential for novel combinatory blockade strategies as antitumoral therapy, and their effects on immune cells expressing the targeted ICs. Preclinical evidence and clinical trials involving the blockade of the various ICs are reported. We finally discuss the rationale of IC co-blockade strategy with respect to its downstream signaling in order to improve effective antitumoral immunity and prevent an increased risk of immune-related adverse events (irAEs).

Matèries

Immunoteràpia, Cèl·lules T

Matèries (anglès)

Immunotherapy, T cells

Citació

Col·leccions

Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ARCHILLA ORTEGA, Adrià, et al. Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity. Journal of Experimental & Clinical Cancer Research. 2022. Vol.  vol 41, num. num 1. ISSN 1756-9966. [consulted: 3 of August of 2026]. Available at: https://hdl.handle.net/2445/183764

Exportar metadades

JSON - METS

Compartir registre